2021•Annals of OncologyOpen access

19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation

İzzet Doğan, Mustafa Gürbüz, Nail Paksoy, N. Khanmamadov, Sezai Vatansever, Pınar Saip, Ahmet Demirkazık, Adnan Aydıner

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Osimertinib, T790M, Medicine, Lung cancer, Acquired resistance, Mutation, Oncology, Resistance mutation

Back to paper search Browse research topics Original source

19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation — Research Paper | ScholarLens